BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ando T, Tsuzuki T, Mizuno T, Minami M, Ina K, Kusugami K, Takamatsu J, Adachi K, El-Omar E, Ohta M. Characteristics of Helicobacter pylori-induced gastritis and the effect of H. pylori eradication in patients with chronic idiopathic thrombocytopenic purpura. Helicobacter. 2004;9:443-452. [PMID: 15361084 DOI: 10.1111/j.1083-4389.2004.00261.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Kuwana M, Ikeda Y. Helicobacter pylori and immune thrombocytopenic purpura: unsolved questions and controversies. Int J Hematol 2006;84:309-15. [PMID: 17118756 DOI: 10.1532/IJH97.06188] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
2 Jackson SC, Beck P, Buret AG, O’Connor PM, Meddings J, Pineo G, Poon MC. Long term platelet responses to Helicobacter pylori eradication in Canadian patients with immune thrombocytopenic purpura. Int J Hematol. 2008;88:212-218. [PMID: 18668306 DOI: 10.1007/s12185-008-0138-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
3 Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Liu Y, Kelton JG, Crowther MA. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica 2009;94:850-6. [PMID: 19483158 DOI: 10.3324/haematol.2008.005348] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Liebman HA, Stasi R. Secondary immune thrombocytopenic purpura: . Current Opinion in Hematology 2007;14:557-73. [DOI: 10.1097/moh.0b013e3282ab9904] [Cited by in Crossref: 49] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
5 Sato R, Murakami K, Okimoto T, Watanabe K, Kodama M, Fujioka T. Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura. J Gastroenterol. 2011;46:991-997. [PMID: 21594563 DOI: 10.1007/s00535-011-0416-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
6 Franchini M. Thrombotic thrombocytopenic purpura: proposal of a new pathogenic mechanism involving Helicobacter pylori infection. Med Hypotheses. 2005;65:1128-1131. [PMID: 16084670 DOI: 10.1016/j.mehy.2005.06.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
7 Emilia G, Luppi M, Zucchini P, Morselli M, Potenza L, Forghieri F, Volzone F, Jovic G, Leonardi G, Donelli A. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood. 2007;110:3833-3841. [PMID: 17652264 DOI: 10.1182/blood-2006-12-063222] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.2] [Reference Citation Analysis]
8 Fujimura K. Helicobacter pylori Infection and Idiopathic Thrombocytopenic Purpura. International Journal of Hematology 2005;81:113-8. [DOI: 10.1532/ijh97.04161] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
9 Nilsson H, Pietroiusti A, Gabrielli M, Zocco MA, Gasbarrini G, Gasbarrini A. Helicobacter pylori and Extragastric Diseases - Other Helicobacters. Helicobacter 2005;10:54-65. [DOI: 10.1111/j.1523-5378.2005.00334.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
10 Ando T, Minami M, Ishiguro K, Maeda O, Watanabe O, Mizuno T, Fujita T, Takahashi H, Noshiro M, Goto H. Changes in biochemical parameters related to atherosclerosis after Helicobacter pylori eradication. Aliment Pharmacol Ther Symp Series 2006;2:58-64. [DOI: 10.1111/j.1746-6342.2006.00026.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
11 Tsumoto C, Tominaga K, Okazaki H, Tanigawa T, Yamagami H, Watanabe K, Nakao T, Koh K, Watanabe T, Fujiwara Y. Long-term efficacy of Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura: 7-year follow-up prospective study. Ann Hematol. 2009;88:789-793. [PMID: 19096845 DOI: 10.1007/s00277-008-0667-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
12 Franchini M, Plebani M, Montagnana M, Veneri D, Lippi G. Pathogenesis, Laboratory, and Clinical Characteristics of Helicobacter pylori-Associated Immune Thrombocytopenic Purpura. Elsevier; 2010. pp. 131-44. [DOI: 10.1016/s0065-2423(10)52005-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Shiota S, Watada M, Matsunari O, Iwatani S, Suzuki R, Yamaoka Y. Helicobacter pylori iceA, clinical outcomes, and correlation with cagA: a meta-analysis. PLoS One. 2012;7:e30354. [PMID: 22279585 DOI: 10.1371/journal.pone.0030354] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
14 Shiota S, Suzuki R, Yamaoka Y. The significance of virulence factors in Helicobacter pylori. J Dig Dis. 2013;14:341-349. [PMID: 23452293 DOI: 10.1111/1751-2980.12054] [Cited by in Crossref: 80] [Cited by in F6Publishing: 63] [Article Influence: 10.0] [Reference Citation Analysis]
15 Ando T, Minami M, Ishiguro K, Maeda O, Watanabe O, Mizuno T, Fujita T, Takahashi H, Noshiro M, Goto H. Changes in biochemical parameters related to atherosclerosis after Helicobacter pylori eradication: HELICOBACTER PYLORI ERADICATION AND ATHEROSCLEROSIS. Alimentary Pharmacology & Therapeutics 2006;24:58-64. [DOI: 10.1111/j.1365-2036.2006.00026.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
16 Kodama M, Kitadai Y, Ito M, Kai H, Masuda H, Tanaka S, Yoshihara M, Fujimura K, Chayama K. Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura. Helicobacter. 2007;12:36-42. [PMID: 17241299 DOI: 10.1111/j.1523-5378.2007.00477.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
17 Campuzano-Maya G. Hematologic manifestations of Helicobacter pylori infection. World J Gastroenterol 2014; 20(36): 12818-12838 [PMID: 25278680 DOI: 10.3748/wjg.v20.i36.12818] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
18 Emilia G, Luppi M, Torelli G. Infectious agents and human immune diseases: Lessons from Helicobacter pylori. The American Journal of Medicine 2005;118:420-1. [DOI: 10.1016/j.amjmed.2005.02.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
19 Arnold DM, Stasi R. Does Helicobacter pylori eradication therapy result in a platelet count improvement in adults with immune thrombocytopenic purpura regardless of H pylori infection? ASH evidence-based review 2008. Hematology Am Soc Hematol Educ Program 2008;:31-2. [PMID: 19074051 DOI: 10.1182/asheducation-2008.1.31] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
20 Rostami N, Keshtkar-Jahromi M, Rahnavardi M, Esfahani FS. Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial. Am J Hematol. 2008;83:376-381. [PMID: 18183613 DOI: 10.1002/ajh.21125] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
21 Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K; Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15:1-20. [PMID: 20302585 DOI: 10.1111/j.1523-5378.2009.00738.x] [Cited by in Crossref: 262] [Cited by in F6Publishing: 241] [Article Influence: 21.8] [Reference Citation Analysis]
22 Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel JB. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009;113:1231-40. [DOI: 10.1182/blood-2008-07-167155] [Cited by in Crossref: 186] [Cited by in F6Publishing: 154] [Article Influence: 14.3] [Reference Citation Analysis]
23 Zhang B, Li Y, Liu X, Wang P, Yang B, Bian D. Association between vacA genotypes and the risk of duodenal ulcer: a meta-analysis. Mol Biol Rep 2014;41:7241-54. [DOI: 10.1007/s11033-014-3610-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
24 Scandellari R, Allemand E, Vettore S, Plebani M, Randi ML, Fabris F. Platelet response to Helicobacter pylori eradication therapy in adult chronic idiopathic thrombocytopenic purpura seems to be related to the presence of anticytotoxin-associated gene A antibodies. Blood Coagul Fibrinolysis. 2009;20:108-113. [PMID: 19786938 DOI: 10.1097/mbc.0b013e32832315d8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ikuse T, Toda M, Kashiwagi K, Maruyama K, Nagata M, Tokushima K, Ito N, Tokita K, Kyodo R, Hosoi K, Jimbo K, Kudo T, Shimizu T. Efficacy of Helicobacter pylori Eradication Therapy on Platelet Recovery in Pediatric Immune Thrombocytopenic Purpura-Case Series and a Systematic Review. Microorganisms 2020;8:E1457. [PMID: 32977477 DOI: 10.3390/microorganisms8101457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Russo G, Miraglia V, Branciforte F, Matarese SM, Zecca M, Bisogno G, Parodi E, Amendola G, Giordano P, Jankovic M. Effect of eradication of Helicobacter pylori in children with chronic immune thrombocytopenia: a prospective, controlled, multicenter study. Pediatr Blood Cancer. 2011;56:273-278. [PMID: 20830773 DOI: 10.1002/pbc.22770] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
27 Li C, Li J, Li Y, Lang S, Yougbare I, Zhu G, Chen P, Ni H. Crosstalk between Platelets and the Immune System: Old Systems with New Discoveries. Adv Hematol 2012;2012:384685. [PMID: 23008717 DOI: 10.1155/2012/384685] [Cited by in Crossref: 71] [Cited by in F6Publishing: 84] [Article Influence: 7.1] [Reference Citation Analysis]
28 Frydman GH, Davis N, Beck PL, Fox JG. Helicobacter pylori Eradication in Patients with Immune Thrombocytopenic Purpura: A Review and the Role of Biogeography. Helicobacter 2015;20:239-51. [PMID: 25728540 DOI: 10.1111/hel.12200] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
29 Liebman H. Other immune thrombocytopenias. Semin Hematol. 2007;44:S24-S34. [PMID: 18096469 DOI: 10.1053/j.seminhematol.2007.11.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
30 Franchini M, Veneri D. Helicobacter pylori-associated immune thrombocytopenia. Platelets. 2006;17:71-77. [PMID: 16421007 DOI: 10.1080/09537100500438057] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
31 Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Liu Y, Kelton JG, Crowther MA. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica. 2009;94:850-856. [PMID: 19483158 DOI: 10.3324/haematol.2008.005348] [Cited by in Crossref: 74] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
32 Satake M, Nishikawa J, Fukagawa Y, Akashi K, Okamoto T, Yoshida T, Hirano A, Maetani N, Iida Y, Sakaida I. The long-term efficacy of Helicobacter pylori eradication therapy in patients with idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol. 2007;22:2233-2237. [PMID: 17559384 DOI: 10.1111/j.1440-1746.2007.04845.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
33 Nagata A, Sekiguchi N, Kurimoto M, Noto S, Takezako N. Significance of lymphocyte counts at diagnosis in the management of ITP: the relationship between lymphocyte counts and treatment success in H. pylori-infected patients. Int J Hematol 2015;101:268-72. [DOI: 10.1007/s12185-015-1737-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
34 Yamanishi S, Iizumi T, Watanabe E, Shimizu M, Kamiya S, Nagata K, Kumagai Y, Fukunaga Y, Takahashi H. Implications for induction of autoimmunity via activation of B-1 cells by Helicobacter pylori urease. Infect Immun. 2006;74:248-256. [PMID: 16368978 DOI: 10.1128/iai.74.1.248-256.2006] [Cited by in Crossref: 53] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
35 Stasi R. Therapeutic strategies for hepatitis- and other infection-related immune thrombocytopenias. Semin Hematol 2009;46:S15-25. [PMID: 19245929 DOI: 10.1053/j.seminhematol.2008.12.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
36 Ishiyama M, Teramura M, Iwabe K, Kato T, Motoji T. Clonally expanded T-cells in the peripheral blood of patients with idiopathic Thrombocytopenic purpura and Helicobacter pylori infection. Int J Hematol. 2006;83:147-151. [PMID: 16513533 DOI: 10.1532/ijh97.05119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
37 Stasi R, Willis F, Shannon MS, Gordon-Smith EC. Infectious causes of chronic immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23:1275-1297. [PMID: 19932434 DOI: 10.1016/j.hoc.2009.08.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
38 Teawtrakul N, Sawadpanich K, Sirijerachai C, Chansung K, Wanitpongpun C. Clinical characteristics and treatment outcomes in patients with Helicobacter pylori-positive chronic immune thrombocytopenic purpura. Platelets. 2014;25:548-551. [PMID: 24176049 DOI: 10.3109/09537104.2013.841883] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
39 Wu SD, Su Y, Fan Y, Zhang ZH, Wang HL, Kong J, Tian Y. Relationship between intraduodenal peri-ampullary diverticulum and biliary disease in 178 patients undergoing ERCP. Hepatobiliary Pancreat Dis Int. 2007;6:299-302. [PMID: 17548255 DOI: 10.1111/j.1523-5378.2007.00502.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]